AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
The double-blind variable placebo lead-in period: Results from two antidepressant clinical trials
Authors: Faries, DE Heiligenstein, JH Tollefson, GD Potter, WZ
Citation: De. Faries et al., The double-blind variable placebo lead-in period: Results from two antidepressant clinical trials, J CL PSYCH, 21(6), 2001, pp. 561-568
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
Authors: Basson, BR Kinon, BJ Taylor, CC Szymanski, KA Gilmore, JA Tollefson, GD
Citation: Br. Basson et al., Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone, J CLIN PSY, 62(4), 2001, pp. 231-238
Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
Authors: Kinon, BJ Basson, BR Gilmore, JA Tollefson, GD
Citation: Bj. Kinon et al., Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia, J CLIN PSY, 62(2), 2001, pp. 92-100
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone
Authors: Dossenbach, MRK Kratky, P Schneidman, M Grundy, SL Metcalfe, S Tollefson, GD Belmaker, RH
Citation: Mrk. Dossenbach et al., Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone, J CLIN PSY, 62, 2001, pp. 28-34
No gender differences in placebo responses of patients with major depressive disorder
Authors: Casper, RC Tollefson, GD Nilsson, ME
Citation: Rc. Casper et al., No gender differences in placebo responses of patients with major depressive disorder, BIOL PSYCHI, 49(2), 2001, pp. 158-160
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
Authors: Tollefson, GD Birkett, MA Kiesler, GM Wood, AJ
Citation: Gd. Tollefson et al., Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine, BIOL PSYCHI, 49(1), 2001, pp. 52-63
A novel augmentation strategy for treating resistant major depression
Authors: Shelton, RC Tollefson, GD Tohen, M Stahl, S Gannon, KS Jacobs, TG Buras, WR Bymaster, FP Zhang, W Spencer, KA Feldman, PD Meltzer, HY
Citation: Rc. Shelton et al., A novel augmentation strategy for treating resistant major depression, AM J PSYCHI, 158(1), 2001, pp. 131-134
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
Authors: Zhang, W Perry, KW Wong, DT Potts, BD Bao, JQ Tollefson, GD Bymaster, FP
Citation: W. Zhang et al., Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex, NEUROPSYCH, 23(3), 2000, pp. 250-262
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms
Authors: Poyurovsky, M Dorfman-Etrog, P Hermesh, H Munitz, H Tollefson, GD Weizman, A
Citation: M. Poyurovsky et al., Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms, INT CLIN PS, 15(3), 2000, pp. 169-173
The effectiveness of olanzapine in treatment-refractory schizophrenia whenpatients are nonresponsive to or unable to tolerate clozapine
Authors: Dossenbach, MRK Beuzen, JN Avnon, M Belmaker, RH Elizur, A Mark, M Munitz, H Schneidman, M Shoshani, D Kratky, P Grundy, SL Tollefson, GD
Citation: Mrk. Dossenbach et al., The effectiveness of olanzapine in treatment-refractory schizophrenia whenpatients are nonresponsive to or unable to tolerate clozapine, CLIN THER, 22(9), 2000, pp. 1021-1034
Olanzapine for psychotic conditions in the elderly
Authors: Street, JS Tollefson, GD Tohen, M Sanger, TM Clark, WS Gannon, KS Wei, HX
Citation: Js. Street et al., Olanzapine for psychotic conditions in the elderly, PSYCHIAT AN, 30(3), 2000, pp. 191-196
Meta-analysis of randomised controlled trials of fluoxetine v. placebo andtricyclic antidepressants in the short-term treatment of major depression
Authors: Bech, P Cialdella, P Haugh, MC Birkett, MA Hours, A Boissel, JP Tollefson, GD
Citation: P. Bech et al., Meta-analysis of randomised controlled trials of fluoxetine v. placebo andtricyclic antidepressants in the short-term treatment of major depression, BR J PSYCHI, 176, 2000, pp. 421-428
Efficacy of olanzapine in acute bipolar mania - A double-blind, placebo-controlled study
Authors: Tohen, M Jacobs, TG Grundy, SL McElroy, SL Banov, MC Janicak, PG Sanger, T Risser, R Zhang, F Toma, V Francis, J Tollefson, GD Breier, A
Citation: M. Tohen et al., Efficacy of olanzapine in acute bipolar mania - A double-blind, placebo-controlled study, ARCH G PSYC, 57(9), 2000, pp. 841-849
Neuropsychological change in early phase schizophrenia during 12 months oftreatment with olanzapine, risperidone, or haloperidol
Authors: Purdon, SE Jones, BDW Stip, E Labelle, A Addington, D David, SR Breier, A Tollefson, GD
Citation: Se. Purdon et al., Neuropsychological change in early phase schizophrenia during 12 months oftreatment with olanzapine, risperidone, or haloperidol, ARCH G PSYC, 57(3), 2000, pp. 249-258
Olanzapine treatment of psychotic and behavioral symptoms in patients withAlzheimer disease in nursing care facilities - A double-blind, randomized,placebo-controlled trial
Authors: Street, JS Clark, WS Gannon, KS Cummings, JL Bymaster, FP Tamura, RN Mitan, SJ Kadam, DL Sanger, TM Feldman, PD Tollefson, GD Breier, A
Citation: Js. Street et al., Olanzapine treatment of psychotic and behavioral symptoms in patients withAlzheimer disease in nursing care facilities - A double-blind, randomized,placebo-controlled trial, ARCH G PSYC, 57(10), 2000, pp. 968-976
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Authors: Tollefson, GD Sanger, TM
Citation: Gd. Tollefson et Tm. Sanger, Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?, SCHIZOPHR R, 35, 1999, pp. S13-S21
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo
Authors: Tollefson, GD Dellva, MA Mattler, CA Kane, JM Wirshing, DA Kinon, BJ
Citation: Gd. Tollefson et al., Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo, J CL PSYCH, 19(5), 1999, pp. 435-443
Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety
Authors: Smith, WT Londborg, PD Blomgren, SL Tollefson, GD Sayler, ME
Citation: Wt. Smith et al., Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety, J CL PSYCH, 19(2), 1999, pp. 125-131
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Authors: Tollefson, GD Andersen, SW
Citation: Gd. Tollefson et Sw. Andersen, Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?, J CLIN PSY, 60, 1999, pp. 23-29
Focus on schizophrenia - Introduction
Authors: Tollefson, GD
Citation: Gd. Tollefson, Focus on schizophrenia - Introduction, BR J PSYCHI, 174, 1999, pp. 1-1
Review of recent clinical studies with olanzapine
Authors: Tollefson, GD Kuntz, AJ
Citation: Gd. Tollefson et Aj. Kuntz, Review of recent clinical studies with olanzapine, BR J PSYCHI, 174, 1999, pp. 30-35
Olanzapine versus haloperidol in the treatment of schizoaffective disorder- Acute and long-term therapy
Authors: Tran, PV Tollefson, GD Sanger, TM Lu, YL Berg, PH Beasley, CM
Citation: Pv. Tran et al., Olanzapine versus haloperidol in the treatment of schizoaffective disorder- Acute and long-term therapy, BR J PSYCHI, 174, 1999, pp. 15-22
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
Authors: Beasley, CM Dellva, MA Tamura, RN Morgenstern, H Glazer, WM Ferguson, K Tollefson, GD
Citation: Cm. Beasley et al., Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol, BR J PSYCHI, 174, 1999, pp. 23-30
The course of depressive symptoms in predicting relapse in schizophrenia: A double-blind, randomized comparison of olanzapine and risperidone
Authors: Tollefson, GD Andersen, SW Tran, PV
Citation: Gd. Tollefson et al., The course of depressive symptoms in predicting relapse in schizophrenia: A double-blind, randomized comparison of olanzapine and risperidone, BIOL PSYCHI, 46(3), 1999, pp. 365-373
Olanzapine versus placebo in the treatment of acute mania
Authors: Tohen, M Sanger, TM McElroy, SL Tollefson, GD Chengappa, R Daniel, DG Petty, F Centorrino, F Wang, R Grundy, SL Greaney, MG Jacobs, TG David, SR Toma, V
Citation: M. Tohen et al., Olanzapine versus placebo in the treatment of acute mania, AM J PSYCHI, 156(5), 1999, pp. 702-709
Risultati: 1-25 | 26-27